UMIN ID: UMIN000002392
Registered date:28/08/2009
Phase 1/2 study of Multiple-Vaccine with CpG-ODN Therapy in Patient with Refractory Colon Cancer to Chemotherapy.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Colon Cancer |
| Date of first enrollment | 2009/08/01 |
| Target sample size | 25 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | RNF43,TOMM34,VEGFR1,VEGFR2 peptides restricted to HLA-A*2402 (3.0mg for each) are administered four times once a week. RNF43,TOMM34,VEGFR1,VEGFR2 peptides restricted to HLA-A*2402 (3.0mg for each) with CpG 7909 (0.02mg/kg) are administered four times once a week. |
Outcome(s)
| Primary Outcome | Evaluation of safety and specific immune response |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 85years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1.Pregnancy 2.Breastfeeding 3.Concurrent treatment with steroids or immunosuppressing agent 4.No other malignancy requiring treatment 5.No severe cardio-vascular disease 6.Decision of unsuitableness by principal investigator or physician-in-charge |
Related Information
| Primary Sponsor | Institute of Medical Science, The university of Tokyo. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | New Energy and Industrial Technology Development Organization |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | |
| Affiliation | Institute of Medical Science, The university of Tokyo Human genome center |
| scientific contact | |
| Name | Atsushi Aruga |
| Address | 8-1, Kawada-chou, Shinjuku-ku, Tokyo Japan |
| Telephone | |
| Affiliation | Tokyo Women's Medical University Surgery |